2023-08-02 16:06:48 ET
- Cerus press release ( NASDAQ: CERS ): Q2 GAAP EPS of -$0.07 misses by $0.01 .
- Revenue of $47.7M (+0.1% Y/Y) beats by $5.92M .
- Adjusting full-year 2023 annual product revenue guidance to the range of $160 million to $165 million from the prior range of $165 million to $170 million given the expected impact of a temporary reduction in U.S. platelet kit shelf life on customer ordering patterns, reduced platelet collections in key regions of EMEA, and new Russia sanctions.
- Cash, cash equivalents, and short-term investments were $84.5 million at June 30, 2023.
For further details see:
Cerus GAAP EPS of -$0.07 misses by $0.01, revenue of $47.7M beats by $5.92M